Frank Hodi, MD
Medical Oncology · Boston, MANPI 1730156324
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $84,831 of the $95,493 with a category attached, or 88.8%. 18 manufacturers reported payments, led by Merck at 35.3% of the total. Reporting peaked in 2020 at $25,913 and has fallen 93.4% since, to $1,716 in 2025.
Across 100 payments — averaging $954.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$34K
- E.r. Squibb & Sons, L.L.C.$19K
- EMD Serono, Inc.$11K
- AstraZeneca$5K
- Immunocore Limited$5K
- Sanofi US Services Inc.$4K
- plus $17K from 12 others
Across 455 payments — averaging $7532.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.4M
- E.r. Squibb & Sons, L.L.C.$725K
- Merck$384K
- GSK$184K
- Pfizer$151K
- Amgen$143K
- plus $414K from 9 others
What the payments were for
- Consulting fees$84,83189%
- Speaking & faculty fees$2,2802%
- Travel & lodging$5,6976%
- Food & beverage$2,6853%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 33 | $33,689 |
| E.r. Squibb & Sons, L.L.C. | 29 | $18,866 |
| EMD Serono, Inc. | 7 | $11,455 |
| AstraZeneca | 1 | $5,480 |
| Immunocore Limited | 2 | $5,200 |
| Sanofi US Services Inc. | 6 | $4,031 |
| F. Hoffmann-la Roche AG | 5 | $3,616 |
| Bayer | 2 | $2,975 |
| Genentech, Inc. | 1 | $2,145 |
| Novartis Pharma AG | 1 | $1,875 |
| Eisai CO., LTD. | 1 | $1,875 |
| Jazz Pharmaceuticals Inc. | 1 | $1,648 |
| Eisai Inc. | 1 | $1,360 |
| Amgen | 3 | $850 |
| Bristol Myers Squibb | 4 | $158 |
| Pfizer | 1 | $100 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Genentech USA, Inc. | 1 | $68 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$5,480
- KIMMTRAK$5,200
- OPDIVO$4,459
- TECENTRIQ$4,425
- NO PRODUCT DISCUSSED$4,010
- MEKINIST$3,750
- LENVIMA$3,235
- KEYTRUDA$1,391
- Non-Covered Product$1,321
- IMLYGIC$800
How this compares
$95,493 in reported general payments places this provider in the 80th percentile of 308 medical oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Boston
- George DemetriBoston$1.6M
- Keith FlahertyBoston$932K
- Alicia MorgansBoston$690K
- Pasi Antero JanneBoston$458K
- Robert HaddadBoston$451K
- Irene GhobrialBoston$431K
- Joaquin Bellmunt MolinsBoston$415K
- Jeremy AbramsonBoston$334K
- Justin GainorBoston$324K
- Narjust FlorezBoston$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.